source
- Zealand Pharma sells rights to rare blood cancer drug rusfertide for up to $100MZealand Pharma entered a royalty purchase and sale agreement with Royalty Pharma, receiving $50 million upfront and the possibility of an additional $50 million after one year. In exchange, Zealan…
- Avalyn Pharma CEO shares personal moment as company prepares for Nasdaq IPOAvalyn Pharma and Generate Biomedicines executives talked about the long hours and challenges of preparing their companies for an initial public offering. Avalyn CEO Lyn Baranowski highlighted a m…